Fideuram Asset Management Ireland dac Takes Position in Bristol Myers Squibb Company $BMY

Key Points

• Fideuram Asset Management Ireland disclosed a new fourth-quarter stake in Bristol Myers Squibb, buying 22,297 shares worth about $1.3 million.
• Bristol Myers Squibb continues to attract institutional interest, with multiple funds adding positions and 76.41% of the stock now held by institutional investors.
• The company recently reported better-than-expected quarterly results, including EPS of $1.58 versus $1.42 expected, and it maintains a 4.4% dividend yield.

Fideuram Asset Management Ireland dac purchased a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 22,297 shares of the biopharmaceutical company's stock, valued at approximately $1,296,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. waypoint wealth counsel bought a new position in shares of Bristol Myers Squibb during the fourth quarter valued at $1,194,000. Life Cycle Investment Partners Ltd purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter valued at $34,406,000. Axxcess Wealth Management LLC increased its holdings in Bristol Myers Squibb by 27.4% in the 4th quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company's stock worth $5,322,000 after buying an additional 21,196 shares in the last quarter. Oppenheimer Asset Management Inc. increased its holdings in Bristol Myers Squibb by 6.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 531,538 shares of the biopharmaceutical company's stock worth $23,972,000 after buying an additional 32,005 shares in the last quarter. Finally, M&G PLC increased its holdings in Bristol Myers Squibb by 1.4% in the 3rd quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company's stock worth $309,833,000 after buying an additional 97,063 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares of the company's stock, valued at $9,820,824.16. The trade was a 15.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is currently owned by insiders.

Bristol Myers Squibb Stock Up 0.5%

BMY stock opened at $57.17 on Friday. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. The stock has a market cap of $116.75 billion, a P/E ratio of 16.06, a PEG ratio of 0.16 and a beta of 0.26. The business's 50-day moving average price is $58.32 and its 200-day moving average price is $56.26.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a return on equity of 64.87% and a net margin of 15.01%.The firm had revenue of $11.49 billion for the quarter, compared to analysts' expectations of $10.93 billion. During the same period in the previous year, the firm earned $1.80 EPS. The business's quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities research analysts forecast that Bristol Myers Squibb Company will post 6.31 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd were given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend was Thursday, April 2nd. Bristol Myers Squibb's payout ratio is presently 70.79%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. Citigroup reiterated a "neutral" rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. HSBC lifted their price objective on Bristol Myers Squibb from $53.00 to $60.00 and gave the stock a "hold" rating in a report on Tuesday, March 17th. Piper Sandler reiterated an "overweight" rating and issued a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Cantor Fitzgerald lifted their price objective on Bristol Myers Squibb from $45.00 to $54.00 and gave the stock a "neutral" rating in a report on Wednesday, April 8th. Finally, Bank of America reduced their price objective on Bristol Myers Squibb from $68.00 to $67.00 and set a "buy" rating for the company in a report on Thursday, April 9th. Eight investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bristol Myers Squibb currently has an average rating of "Hold" and an average price target of $61.31.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: BMS reported encouraging late-stage data for mezigdomide, saying the experimental CELMoD cut the risk of disease progression or death by more than 50% versus standard of care in relapsed or refractory multiple myeloma. That is the kind of readout investors watch for because it strengthens the case for a future commercial opportunity. Article Title
• Positive Sentiment: The company also highlighted mezigdomide data in a business update, reinforcing optimism around its broader oncology pipeline and suggesting Celgene-derived assets continue to support long-term growth prospects. Article Title
• Positive Sentiment: Bristol Myers Squibb said it is backing a new cell-therapy combination in an early gastrointestinal cancer trial, which adds another potential pipeline catalyst and underscores continued investment in high-value cancer programs. Article Title
• Positive Sentiment: BMS also announced a strategic partnership with Anthropic to use Claude across research, clinical development, manufacturing, commercial, and corporate functions, a move that could improve productivity and speed decision-making over time. Article Title

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.